Advertisement

Orthopédie Traumatologie

, Volume 4, Issue 1, pp 5–8 | Cite as

Ostéolyse tumorale maligne métastatique Données actuelles sur la physiopathologie et le traitement

  • P. Orcel
Traitement des métastases osseuses
  • 16 Downloads

Résumé

Les métastases ostéolytiques des cancers sont à l'origine de douleurs et de fractures pathologiques responsables d'une importante invalidité altérant la qualité de survie des patients. Ces destructions osseuses sont dues à une augmentation de la résorption osseuse, liée à la stimulation des ostéoclastes par des médiateurs sécrétés localement par les cellules tumorales et médullaires. Les bisphosphonates, puissants agents anti-ostéoclastiques, ont une bonne efficacité sur les douleurs osseuses, la prévention des fractures et des épisodes hypercalcémiques.

Mots-clés

Métastases osseuses Ostéoclaste Cytokines 

Current concepts in pathophysiology and management of osteolytic malignant metastases

Abstract

Osteolytic metastases are the cause of pain and pathological fractures with marked disability affecting the patient's quality of life. The bone destruction is due to an increase of bone resorption, linked to stimulation of osteoclasts by mediators secreted locally by tumour and medullary cells. Bisphosphonates, strong anti-osteoclastic agents, are effective for bone pain, prevention of fractures and the treatment of hypercalcaemic episodes.

Key words

Bone Metastases Osteoclast Cytokines 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliographie

  1. 1.
    Elomaa I, Blomqvist C, Porkka L, Lamberg-Allardt C, Borgstrom GH (1987) Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone 8: S53-S56PubMedGoogle Scholar
  2. 2.
    Fleisch H (1987) Bisphosphonates, history and experimental basis. Bone 8: S23-S28CrossRefPubMedGoogle Scholar
  3. 3.
    Galasko CBS (1976) Mechanisms of bone destruction in the development of skeletal metastases. Nature 263: 507–508CrossRefPubMedGoogle Scholar
  4. 4.
    Galasko CBS (1976) Relationship of bone destruction in skeletal metastases to osteoclast activation and prostaglandins. Nature 263: 508–510CrossRefPubMedGoogle Scholar
  5. 5.
    Garattini S, Guaitani A, Mantovani A (1987) Effect of etidronate disodium on the interactions betwen malignancy and bone. Am J Med 82 [Suppl 2A]: 29–33CrossRefPubMedGoogle Scholar
  6. 6.
    Goustin AS, Leof EB, Shipley GD, Moses HL (1986) Growth factors and cancer. Cancer Res 46: 1015–1029PubMedGoogle Scholar
  7. 7.
    Krempien B, Wingen F, Eichmann T, Müller M, Schmähl D (1988) Protective effects of a prophylactic treatment with the bisphosphonate 3-amino-l-hydroxypropane-1,1-bisphosphonic acid on the development of tumor osteopathies in the rat: experimental studies with the Walker carcinosarcoma 256. Oncology 45: 41–46CrossRefPubMedGoogle Scholar
  8. 8.
    Magro C, Orr FW, Manishen WJ, Sivananthan K, Mokashi SS (1985) Adhesion, chemotaxis, and agregation of Walker carcinosarcoma cells in response to products of resorbing bone. J Natl Cancer Inst 74: 829–838PubMedGoogle Scholar
  9. 9.
    Manishen WJ, Sivananthan K, Orr FW (1986) Resorbing bone stimulates tumor cell growth. Am J Pathol 123: 39–45PubMedPubMedCentralGoogle Scholar
  10. 10.
    Morton AR, Cantrill JA, Pillai GV, McMahon A, Anderson DC, Howell A (1988) Sclerosis of bone metastases in response to amino hydroxypropylidene-1,1-bisphosphonate (APD) in patients with carcinoma of the breast. Br Med J 297: 772–773CrossRefGoogle Scholar
  11. 11.
    Mundy GR (1991) Mechanisms of osteolytic bone destruction. Bone 12 [Suppl 1]: S1-S6CrossRefPubMedGoogle Scholar
  12. 12.
    Orcel Ph, Cohen-Solal M, de Vernejoul MC, Kuntz D (1992) Déminéralisations osseuses et cytokines. Rev Rhum 59: 16–22Google Scholar
  13. 13.
    Orr W, Varani J, Gondek M, Ward PA, Mundy GR (1979) Chemotactic responses of tumor cells to products of resorbing bone. Science 203: 176 178CrossRefPubMedGoogle Scholar
  14. 14.
    Van Holten-Verzantvoort AT, Bijvoet OLM, Cleton FJ, Hermans J, Kroon HM, Harinck HIJ (1987) Reduced morbidity from skeletal metastases in breast cancer patients during long term bisphosphonatre (APD) treatment. Lancet 2: 983–985CrossRefPubMedGoogle Scholar
  15. 15.
    Zetter B (1990) The cellular basis of sitespecific tumor metastasis. N Engl J Med 322: 605–612CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • P. Orcel
    • 1
  1. 1.INSERM Unité 349Centre Viggo Petersen, Hôpital LariboisièreParisFrance

Personalised recommendations